Primer probe composition, kit and detection method for detecting hypertensive drug gene polymorphism
By designing a primer probe composition for detecting hypertension-related genes, the problem of difficulty in detecting multiple gene polymorphisms in the prior art is solved, and efficient and low-cost genotype detection under a single channel is achieved, satisfying the Clinical needs.
Patent Information
- Application Number
- CN202411442837.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to detect the polymorphisms of multiple hypertension-related genes in the same tube at the same time, resulting in low detection efficiency, high cost and cumbersome operation, which cannot meet clinical needs.
A primer probe composition is designed, including primer probes for detecting polymorphisms of ADRB1, CYP2D6, CYP2C9, CYP3A5, AGTR1, NPPA and ACE genes, which can be amplified simultaneously in the same reaction tube and quantified by fluorescence. The qPCR detection platform detects the polymorphisms of seven genes related to hypertension-guided medications.
The genotypes of 7 hypertensive drug-related genes were realized under a single channel, which significantly improved the detection efficiency, reduced costs, simplified operations, and met the clinical testing needs.
Smart Images

Figure CN119020487A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of molecular biology, and in particular to a primer-probe combination, a kit and a detection method thereof for detecting gene polymorphism of hypertension medication. Background Art
[0002] Clinical practice has found that there are large differences in the effectiveness and adverse reactions of individual drug responses in the treatment of hypertension, and genetic polymorphism is an important factor affecting the individual differences in drug response.
[0003] Commonly used antihypertensive drugs include angiotensin II receptor antagonists (ARBs), angiotensin converting enzyme inhibitors (ACEIs), beta-blockers, thiazide diuretics, and calcium channel blockers (CCBs).
[0004] Among them, angiotensin II is an important humoral factor of the renin-angiotensin system (RAAS). More than 90% of its effects are mediated by the angiotensin II type 1 receptor encoded by the AGTR1 gene, and it is metabolized by the enzyme encoded by CYP2C9. ARB drugs act on the AGTR1 gene target. The 1166A>C gene polymorphism of AGTR1 can affect the therapeutic effect of ARB drugs. A1166A has normal sensitivity to drugs and a good antihypertensive effect; A1166C and C1166C have reduced sensitivity to drugs and poor antihypertensive effects. The main genetic variation in the Chinese population is the CYP2C9*3 genotype, which leads to reduced enzyme activity. The guidelines recommend that the antihypertensive effect of the ARB drug losartan is reduced in individuals with the CYP2C9*1 / *3 genotype, and the dosage should be appropriately increased to enhance the antihypertensive effect.
[0005] The sensitivity of β-blockers is related to the ADRB1 1165G>C gene polymorphism, and the metabolism is mainly related to the CYP2D6 gene polymorphism. The gene ADRB1 encodes the β1-adrenergic receptor (β1-AR). β1-AR and β-blockers are the main target receptors for β-blockers to exert their antihypertensive effects. β-blockers and β1-adrenergic receptors (β1-AR) are the main target receptors for β-blockers to exert their antihypertensive effects. ADRB1 (β-blockers) is related to the sensitivity of the target receptors. G / G type: normal receptor sensitivity, normal sensitivity to β-blockers, and normal efficacy; G / C type: slightly higher receptor sensitivity, slightly higher sensitivity to β-blockers, and slightly better efficacy; C / C type: higher receptor sensitivity, higher sensitivity to β-blockers, and better efficacy; β-blockers and CYP2D6β-blockers are mainly metabolized into inactive products in the body by CYP2D6 metabolizing enzymes. At present, the common alleles of CYP2D6 that cause reduced enzyme activity in the Chinese population have been found to include CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*10, with allele frequencies of 1%, 1%, 6% and 53% respectively. CYP2D6 (β-blockers) is related to drug metabolism. C / C type: normal enzyme activity, normal drug metabolism ability, normal drug efficacy on β-blockers, indicating normal risk of side effects; C / T type: slightly lower enzyme activity, slightly lower drug metabolism ability, slightly poor drug efficacy on β-blockers, indicating slightly higher risk of side effects; T / T type: lower enzyme activity, lower drug metabolism ability, poor drug efficacy on β-blockers, indicating higher risk of side effects.
[0006] Angiotensin converting enzyme (ACE) is a zinc metallopeptidase widely distributed in endothelial cells and epithelial cells. It plays an important role in the renin-angiotensin-aldosterone (RAAS) system. ACEI exerts its antihypertensive effect by competitively inhibiting ACE. The ACE gene is located on chromosome 17, including 26 exons and 25 introns. The I / D polymorphism of the ACE gene is determined by the presence or absence of a 287bp DNA fragment in intron 16. The ACE allele containing this fragment is called the I allele, and the ACE allele without this fragment is called the D allele, resulting in three different genotypes: I / I type: that is, the fragment is inserted into chromosome 17 for insertion homozygotes (I / I type), D / D type: the fragment is missing for deletion homozygotes (D / D type), and I / D type: if the fragment is inserted in one chromosome and missing in another chromosome, it is a heterozygote. Studies on healthy people in my country show that the distribution frequencies of II, ID, and DD genotypes are 41.5%, 38.4%, and 20.1%, respectively. Through oral administration of ACEI drugs to 108 elderly patients with grade 1 hypertension, it was found that the DD genotype group had the best antihypertensive effect, followed by the ID group, and the II group was the worst. This indicates that the ACE I / D gene polymorphism is related to the antihypertensive effect of ACE inhibitors.
[0007] In my country, more than 50% of hypertensive patients use CCBs. This type of drug lowers blood pressure by blocking calcium channels. The CYP3A5 gene is closely related to the efficacy of calcium ion antagonists. The CYP3A5 gene mutation is the main reason for the difference in enzyme activity. The mutation will significantly reduce its enzyme activity, slow down the metabolism of substrate drugs, and significantly increase the risk of drug effects and side effects. CYP3A5*3 6986A>G site, CYP3A5 has more than 30 SNP sites, among which the *3 site mutation (intron 3 6986A>G mutation) causes DNA transcription to terminate prematurely and leads to enzyme inactivation, which is a key factor in determining CYP3A5 expression and enzyme activity. Homozygous mutant individuals (GG or *3 / *3) cannot produce active CYP3A5 enzymes, which are called slow metabolizers; wild-type (AA or *1 / *1) and heterozygous (AG or *1 / *3) individuals can produce active CYP3A5 enzymes, which are called fast metabolizers.
[0008] NPPA plays an important role in regulating vascular tone and sodium balance. This gene encodes the precursor of ANP (atrial natriuretic peptide), which acts as a diuretic and regulates extracellular fluid volume and electrolyte homeostasis. There is a genetic polymorphism in NPPA 2238T>C, which is not only related to the risk of hypertension, but also to the efficacy of hypertension drug treatment, which will affect the efficacy of diuretics and CCBs. Studies have shown that the effect of hypertension drugs in the treatment of cardiovascular disease and hypertension is affected by the polymorphism of NPPA T2238C. Patients with NPPA gene T2238C mutation are more sensitive to diuretics and have better treatment effects. For patients with T2238T genotype, the calcium channel blocker amlodipine is better than other diuretics and angiotensin converting enzyme inhibitors.
[0009] Although there are many technologies for detecting gene polymorphisms, the most commonly used ones are PCR, first-generation sequencing, second-generation sequencing and gene chip methods. However, these technologies have many shortcomings in application, such as cumbersome operation, long detection cycle, low sensitivity and poor specificity. Among them, although the ordinary qPCR (fluorescence-probe method) platform detection can detect multiple sites simultaneously, the polymorphism detection of a gene requires multiple channels, resulting in the need to prepare corresponding reagents for each gene when detecting multiple genes on the same instrument, and each reagent needs to be added with a template separately, which will increase the amount of template in the test sample, which not only increases the cost of the detection reagents, but also has cumbersome operation and low detection efficiency, and cannot meet clinical detection needs.
[0010] Therefore, the prior art needs to be further improved. Summary of the invention
[0011] In view of the technical problem that the fluorescent quantitative qPCR detection platform in the prior art is difficult to detect the polymorphism of multiple genes in the same tube, the present invention provides a primer probe combination, a kit and a detection method for detecting the polymorphism of hypertension medication genes. The primer probe combination and the kit can simultaneously detect the polymorphism of 7 hypertension guidance medication-related gene sites in the same tube, with high detection efficiency and significantly reduced costs.
[0012] To solve the above problems, this application provides the following technical solutions:
[0013] In the first aspect, the present application provides a primer-probe composition for detecting gene polymorphisms of hypertension medication, which includes the following primer-probe combinations for detecting the 1165G>C site of the ADRB1 gene, the 100C>T site of the CYP2D6*10 gene, the 1075A>C site of the CYP2C9*3 gene, the 6986A>G site of the CYP3A5*3 gene, the 1166A>C site of the AGTR1 gene, the 2238T>C site of the NPPA gene, and the ACE(I / D) gene:
[0014] The primer probes used to detect the 100C>T site of the CYP2D6*10 gene are: a forward primer F1 whose sequence is shown in SEQ ID NO.1, a reverse primer R1 whose sequence is shown in SEQ ID NO.2, and a fluorescent probe T1 whose sequence is shown in SEQ ID NO.3;
[0015] The primer probes used to detect the 1075A>C site of the CYP2C9*3 gene are: a forward primer F2 whose sequence is shown in SEQ ID NO.4, a reverse primer R2 whose sequence is shown in SEQ ID NO.5, and a fluorescent probe T2 whose sequence is shown in SEQ ID NO.6;
[0016] The primer probes used to detect the 6986A>G site of the CYP3A5*3 gene are: a forward primer F3 whose sequence is shown in SEQ ID NO.7, a reverse primer R3 whose sequence is shown in SEQ ID NO.8, and a fluorescent probe T3 whose sequence is shown in SEQ ID NO.9;
[0017] The primer probes used to detect the 1165G>C site of the ADRB1 gene are: a forward primer F4 whose sequence is shown in SEQ ID NO.10, a reverse primer R4 whose sequence is shown in SEQ ID NO.11, and a fluorescent probe T4 whose sequence is shown in SEQ ID NO.12;
[0018] The primers and probes used to detect the 1166A>C site of the AGTR1 gene are: a forward primer F5 having a sequence as shown in SEQ ID NO.13, a reverse primer R5 having a sequence as shown in SEQ ID NO.14, and a fluorescent probe T5 having a sequence as shown in SEQ ID NO.15;
[0019] The primers and probes used to detect the 2238T>C site of the NPPA gene are: a forward primer F6 having a sequence as shown in SEQ ID NO.16, a reverse primer R6 having a sequence as shown in SEQ ID NO.17, and a fluorescent probe T6 having a sequence as shown in SEQ ID NO.18;
[0020] The primer probes used to detect the ACE (I / D) gene are: a forward primer F7 whose sequence is shown in SEQ ID NO.19, a reverse primer R7 whose sequence is shown in SEQ ID NO.20, and a fluorescent probe T7 whose sequence is shown in SEQ ID NO.21.
[0021] The above seven sets of primer-probe combinations are cleverly designed and can be amplified simultaneously in the same reaction tube. By adding a sample to be tested into the tube, the polymorphisms of seven hypertension medication-related genes in the sample to be tested can be simultaneously detected through a fluorescent quantitative qPCR detection platform, thereby clarifying the medication regimens for the seven types of hypertension medications.
[0022] Not only does there not exist any mutual interference problem among the above seven groups of primers and probes, but each group of primers and probes has high binding specificity to its respective test site, and the simultaneous detection of polymorphisms of seven target sites can be completed in a single-hole reaction tube, greatly improving the detection throughput.
[0023] Optionally, the primer-probe composition for detecting gene polymorphisms for hypertension medication also includes primer probes for detecting internal reference genes: an upstream primer RP-F having a sequence as shown in SEQ ID NO.22, a downstream primer RP-R having a sequence as shown in SEQ ID NO.23, and a fluorescent probe RP-P having a sequence as shown in SEQ ID NO.24.
[0024] Optionally, in the primer-probe composition, the 5' end of the fluorescent probe is labeled with a fluorescent reporter group, and the 3' end of the fluorescent probe is labeled with a fluorescent quencher group, the fluorescent reporter group is selected from any one of FAM, ROX, CY5 and VIC; the quencher group is BHQ1, BHQ2 or BHQ3.
[0025] Different fluorescent groups are set for fluorescent probes of different gene loci for differentiation, and melting curve analysis is performed by using detection probes labeled with reporter groups and quencher groups.
[0026] Preferably, in the primer-probe composition, the 5' end of the fluorescent probe for the 1075A>C site of the CYP2C9*3 gene and the 100C>T site of the CYP2D6*10 gene is labeled with a FAM fluorescent group, and the 3' end is labeled with a quencher group BHQ1; the 5' end of the fluorescent probe for the 6986A>G site of the CYP3A5*3 gene and the 1165G>C site of the ADRB1 gene is labeled with a CY5 fluorescent group, and the 3' end is labeled with a quencher group BHQ3; the 5' end of the fluorescent probe for the 1166A>C site of the AGTR1 gene and the 2238T>C site of the NPPA gene is labeled with a ROX fluorescent group, and the 3' end is labeled with a quencher group BHQ2; the 5' end of the fluorescent probe for the ACE(I / D) gene and RP is labeled with a VIC fluorescent group, and the 3' end is labeled with a quencher group BHQ1.
[0027] The primer-probe combination of the present invention is modified with multiple fluorescent groups, namely, FAM, ROX, CY5 and VIC, respectively, to meet the requirements of multi-channel and high-throughput detection, and greatly improve the detection efficiency.
[0028] In a second aspect, the present application also provides a kit for detecting genetic polymorphisms of hypertension medications, which comprises the above-mentioned primer-probe combination.
[0029] The primer-probe combination in the kit is in the form of lyophilized powder or solution. The lyophilized powder form is more convenient for the transportation and long-term storage of the primer-probe combination, ensuring that the enzyme is not easily inactivated.
[0030] Optionally, the kit includes: a reaction premix and an enzyme mixture, and the reaction premix includes: the aforementioned primer-probe combination and a reaction buffer.
[0031] Optionally, the enzyme mixture includes Taq DNA polymerase and UDG enzyme. UDG enzyme is uracil-DNA glycosylase, which is used to prevent contamination of PCR amplification products and ensure the accuracy of the test results.
[0032] Optionally, the final concentration of the forward primer in the reaction premix is in the range of 0.1 μM to 0.2 μM, the final concentration of the reverse primer is in the range of 2 μM to 4 μM, and the final concentration of the probe is in the range of 0.2 μM to 0.4 μM.
[0033] Optionally, the kit further comprises: a positive control and a negative control; the positive control is a plasmid carrying 7 kinds of gene heterozygous mutation genotype sequence fragments and an RP gene sequence fragment, and the negative control is TE Buffer.
[0034] In a third aspect, the present application also provides a kit for detecting gene polymorphisms of hypertension medications and its use in detecting gene polymorphisms of hypertension medications.
[0035] Optionally, in the application, the sample to be tested includes but is not limited to at least one of a throat swab, saliva and blood.
[0036] In a fourth aspect, the present application also provides a method for detecting gene polymorphisms of hypertension medication, comprising the following steps:
[0037] S1, adding the sample to be tested into a PCR reaction tube containing the aforementioned primer-probe combination and PCR reaction solution, mixing and then amplifying;
[0038] S2. Detect the genotype of the target detection site according to the difference in Tm values of the melting curves of each channel in the PCR reaction system.
[0039] Optionally, the amplification conditions of step S1 are:
[0040] (1) Pre-denaturation at 95°C for 30 seconds;
[0041] (2) 95°C for 5 seconds, 60°C for 10 seconds, for 40 cycles;
[0042] (3) 95°C for 3 minutes; 40°C for 3 minutes;
[0043] (4) Melting program: 45°C-80°C, heating rate 0.05°C / s.
[0044] Optionally, in the above step (4), fluorescence is detected at 45°C-80°C, and the detection channels are: FAM, ROX, CY5, VIC.
[0045] The principle of the above method for detecting gene polymorphism of hypertension medication is:
[0046] Under certain temperature conditions, the probe can form a double strand with its complementary sequence. At this time, the reporter group and the quencher group on the probe are separated, resulting in the quencher group being unable to absorb the signal emitted by the reporter group, so that the device can detect the strongest fluorescence signal. As the temperature continues to rise, the two double strands begin to separate, causing the probe to present a single-stranded free curling state. At this time, the reporter group and the quencher group on the probe will be close again, and the signal emitted by the reporter group will be absorbed by the quencher group. Therefore, as the temperature continues to rise, the measured signal will gradually weaken. When the two double strands are completely separated, all probes present a single-stranded free curling state. At this time, all the signals emitted by the probes are absorbed by the quencher group, and the signal emitted by the probe is basically undetectable at this time. Therefore, by detecting the fluorescence signal emitted by the double strand during the heating or cooling process, the hybridization and separation process of the probe and its complementary sequence can be observed, and a curve in which the signal intensity changes in real time with the temperature change is formed. Then, by derivation analysis of the curve, a melting curve with the signal intensity change rate as the ordinate and the temperature as the abscissa is obtained. The peak in the curve is the melting peak, and the temperature corresponding to the melting peak is the Tm of the double strand. Generally speaking, the higher the match between the probe and the complementary sequence, the higher the melting point of the double strand. Therefore, by detecting the Tm of the double strand, the sequence base complementary to the probe in the double strand can be determined. In this article, "melting peak" and "Tm" have the same meaning and can be used interchangeably. Through the fluorescent quantitative PCR detection technology of the melting curve, genotyping can be performed according to the peak shape of the melting curve and the Tm value. It is simple to operate, low cost, and has high sensitivity and accuracy.
[0047] Optionally, in step S2, the specific analysis and judgment method is:
[0048] The site to be detected is the 100C>T site of the CYP2D6*10 gene, the detection channel is FAM, the melting curve is a single peak, and when the Tm value of the peak is 73.79±0.5, it indicates that the genotype of the detection site is TT. If the value of the single peak is 70.08±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 70.08±0.5 and 73.79±0.5 respectively, it indicates that the genotype of the site is TC.
[0049] The site to be detected is the 1075A>C site of the CYP2C9*3 gene, the detection channel is FAM, the melting curve is a single peak, and when the Tm value of the single peak is 51.25±0.5, it indicates that the genotype of the detection site is AA. If the value of the single peak is 60.59±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 51.25±0.5 and 60.59±0.5 respectively, it indicates that the genotype of the site is AC.
[0050] The site to be detected is the 6986A>G site of the CYP3A5*3 gene, the detection channel is Cy5, the melting curve is a single peak, and when the Tm value of the single peak is 67.84±0.5, it indicates that the genotype of the detection site is AA. If the value of the single peak is 62.91±0.5, it indicates that the genotype of the site is GG. If the melting curve is a double peak, and the Tm values of the double peaks are 67.84±0.5 and 62.91±0.5 respectively, it indicates that the genotype of the site is AG.
[0051] The site to be detected is the 1165G>C site of the ADRB1 gene, the detection channel is Cy5, the melting curve is a single peak, and when the Tm value of the single peak is 60.12±0.5, it indicates that the genotype of the detection site is GG. If the value of the single peak is 66.98±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 60.12±0.5 and 66.98±0.5 respectively, it indicates that the genotype of the site is GC.
[0052] The site to be detected is the AGTR1 gene 1166A>C site, the detection channel is ROX, the melting curve is a single peak, and when the Tm value of the single peak is 57.04±0.5, it indicates that the genotype of the detection site is AA. If the value of the single peak is 65.17±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 57.04±0.5 and 65.17±0.5 respectively, it indicates that the genotype of the site is AC.
[0053] The site to be detected is the NPPA gene 2238T>C site, the detection channel is ROX, the melting curve is a single peak, and when the Tm value of the single peak is 55.08±0.5, it indicates that the genotype of the detection site is TT. If the value of the single peak is 61.24±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 55.08±0.5 and 61.24±0.5 respectively, it indicates that the genotype of the site is TC.
[0054] The site to be detected is the ACE (I / D) gene, the detection channel is VIC, the melting curve is a single peak, and when the Tm value of the single peak is 72.34±0.5, it indicates that the genotype of the detection site is type I. If the value of the single peak is 58.59±0.5, it indicates that the genotype of the site is type D. If the melting curve is a double peak, and the Tm values of the double peaks are 58.59±0.5 and 72.34±0.5 respectively, it indicates that the genotype of the site is type I / D.
[0055] The present invention has the following beneficial effects:
[0056] 1. The present invention provides the above-mentioned kit by screening a suitable primer-probe combination and optimizing the reaction system, so as to realize the judgment of the genotype of a single gene by Tm value and melting peak shape under a single channel, and simultaneously detect the genotypes of 7 hypertension medication genes in a single tube system (i.e., ADRB1 gene 1165G>C site, CYP2D6*10 gene 100C>T site, CYP2C9*3 gene 1075A>C site, CYP3A5*3 gene 6986A>G site, AGTR1 gene 1166A>C site, NPPA gene 2238T>C site, ACE(I / D) gene genotype).
[0057] 2. The primer probe combination and kit of the present application can simultaneously detect the genotypes of the above seven hypertension medication genes in throat swabs, saliva and blood samples, and the samples to be tested do not require additional processing. Throat swabs, saliva and blood samples can be used directly for detection to guide clinical hypertension medication. The above primer probe combination and kit are simple and convenient to use, and have high detection efficiency.
[0058] 3. Through the detection method of the present application, it is possible to analyze the Tm value of the fusion peak of the melting curve of different detection channels in the same reaction tube, thereby simultaneously determining the genotypes of seven hypertension medication gene loci. The sampling is convenient, the operation steps are simple, the detection cycle is short, the detection efficiency is high, and the use of detection samples is saved, which greatly reduces the detection cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 This is the melting curve of the 100C>T site of the CYP2D6*10 gene;
[0060] Figure 2 This is the melting curve of the 1075A>C site of the CYP2C9*3 gene;
[0061] Figure 3 It is the melting curve of the 6986A>G site of the CYP3A5*3 gene;
[0062] Figure 4It is the melting curve of the 1165G>C site of the ADRB1 gene;
[0063] Figure 5 It is the melting curve of the 1166A>C site of the AGTR1 gene;
[0064] Figure 6 It is the melting curve of the 2238T>C site of the NPPA gene;
[0065] Figure 7 This is the melting curve of ACE (I / D) gene. DETAILED DESCRIPTION
[0066] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention. In the present invention, unless otherwise specified, the equipment and raw materials used can be purchased from the market or are commonly used in the art. The methods in the following embodiments are conventional methods in the art unless otherwise specified.
[0067] Example 1 Preparation of a kit for detecting gene polymorphisms of hypertension medications
[0068] 1. Design of primers and probes
[0069] According to the sequence characteristics and mutual influence of seven hypertension medication gene target sites to be detected (ADRB1 gene 1165G>C site, CYP2D6*10 gene 100C>T site, CYP2C9*3 gene 1075A>C site, CYP3A5*3 gene 6986A>G site, AGTR1 gene 1166A>C site, NPPA gene 2238T>C site, ACE (I / D) gene), seven sets of primer-probe combinations were designed that can simultaneously and specifically amplify each target gene site in one tube. The sequence of each set of primer-probe combinations is shown in Table 1 below, and the sequences and probes were synthesized.
[0070] Table 1 Primers and fluorescent probes
[0071]
[0072]
[0073] In this technology, the primer-probe combination also includes an internal reference primer-probe combination: RP-F forward primer, RP-R reverse primer, RP-P fluorescent probe (see Table 1 above for details). The internal reference control can indicate the occurrence of false negatives and is used to monitor the collection, transportation, extraction and amplification process of the sample to be tested to avoid false negatives interfering with the test results.
[0074] In addition, the fluorescent groups are labeled as follows:
[0075] The fluorescent probes for the 1075A>C site of the CYP2C9*3 gene and the 100C>T site of the CYP2D6*10 gene were labeled with the FAM fluorescent group at the 5' end and the quencher group BHQ1 at the 3' end; the fluorescent probes for the 6986A>G site of the CYP3A5*3 gene and the 1165G>C site of the ADRB1 gene were labeled with the CY5 fluorescent group at the 5' end and the quencher group BHQ3 at the 3' end; the fluorescent probes for the 1166A>C site of the AGTR1 gene and the 2238T>C site of the NPPA gene were labeled with the ROX fluorescent group at the 5' end and the quencher group BHQ2 at the 3' end; the fluorescent probes for the ACE(I / D) gene and RP were labeled with the VIC fluorescent group at the 5' end and the quencher group BHQ1 at the 3' end.
[0076] 2. This embodiment also provides a kit for simultaneously detecting the genotypes of seven hypertension medication genes
[0077] The kit includes: reaction solution, enzyme mixture, positive control substance and negative control substance.
[0078] The reaction solution includes the seven sets of primer-probe compositions, an internal reference primer-probe composition, a PCR reaction buffer and RNase free H2O.
[0079] The specific components of the reaction system used in the amplification of the kit are shown in Table 2.
[0080] Table 2 Components and addition amounts of reaction system A
[0081]
[0082]
[0083] 3. How to use the kit
[0084] After configuring the reaction system according to the above method, each reaction system is placed on the qPCR detection platform for detection. The detection method is as follows:
[0085] Step 1. Reagent preparation
[0086] (1) First, take all reagents out of the refrigerator and equilibrate them to room temperature. The standard for PCR reaction solution is: take n×35.98μL of reaction solution and n×4.02μL of enzyme mixture and add them to a 1.5mL centrifuge tube. Vortex the centrifuge tube for a few seconds and centrifuge for a few seconds.
[0087] (2) Aliquoting of PCR reaction solution: Aliquot 40 μL of PCR reaction solution into thin-walled PCR reaction tubes.
[0088] Step 2, adding samples: the throat swab after sampling is stored in 0.9% NaCl, the PCR reaction tube containing the PCR reaction solution in step S1 is taken out, 10 μL of the sample to be tested, the positive control and the negative control are directly added, the tube cap is tightly closed, and the tube is shaken evenly and then centrifuged instantly at a speed of 3000 rpm / min for 20 seconds;
[0089] Step 3, amplification detection: put the PCR reaction tube obtained in step S2 into a fluorescent PCR amplification instrument for amplification detection, and the reaction program is set as shown in Table 3;
[0090] Table 3 Fluorescence amplification instrument reaction program
[0091]
[0092]
[0093] Wherein, in step 04, fluorescence is detected at 45°C-80°C, and the detection channels are: FAM, ROX, CY5, and VIC.
[0094] Step S4, result determination: Determine the sample detection result according to the melting curve diagrams of different channels, and distinguish the genotype of the target gene site using the Tm value and the melting peak shape.
[0095] The specific analysis and judgment methods are:
[0096] The site to be detected is the 100C>T site of the CYP2D6*10 gene, the detection channel is FAM, the melting curve is a single peak, and when the Tm value of the peak is 73.79±0.5, it indicates that the genotype of the detection site is TT. If the value of the single peak is 70.08±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 70.08±0.5 and 73.79±0.5 respectively, it indicates that the genotype of the site is TC.
[0097] The site to be detected is the 1075A>C site of the CYP2C9*3 gene, the detection channel is FAM, the melting curve is a single peak, and when the Tm value of the single peak is 51.25±0.5, it indicates that the genotype of the detection site is AA. If the value of the single peak is 60.59±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 51.25±0.5 and 60.59±0.5 respectively, it indicates that the genotype of the site is AC.
[0098] The site to be detected is the 6986A>G site of the CYP3A5*3 gene, the detection channel is Cy5, the melting curve is a single peak, and when the Tm value of the single peak is 67.84±0.5, it indicates that the genotype of the detection site is AA. If the value of the single peak is 62.91±0.5, it indicates that the genotype of the site is GG. If the melting curve is a double peak, and the Tm values of the double peaks are 67.84±0.5 and 62.91±0.5 respectively, it indicates that the genotype of the site is AG.
[0099] The site to be detected is the 1165G>C site of the ADRB1 gene, the detection channel is Cy5, the melting curve is a single peak, and when the Tm value of the single peak is 60.12±0.5, it indicates that the genotype of the detection site is GG. If the value of the single peak is 66.98±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 60.12±0.5 and 66.98±0.5 respectively, it indicates that the genotype of the site is GC.
[0100] The site to be detected is the AGTR1 gene 1166A>C site, the detection channel is ROX, the melting curve is a single peak, and when the Tm value of the single peak is 57.04±0.5, it indicates that the genotype of the detection site is AA. If the value of the single peak is 65.17±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 57.04±0.5 and 65.17±0.5 respectively, it indicates that the genotype of the site is AC.
[0101] The site to be detected is the NPPA gene 2238T>C site, the detection channel is ROX, the melting curve is a single peak, and when the Tm value of the single peak is 55.08±0.5, it indicates that the genotype of the detection site is TT. If the value of the single peak is 61.24±0.5, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 55.08±0.5 and 61.24±0.5 respectively, it indicates that the genotype of the site is TC.
[0102] The site to be detected is the ACE (I / D) gene, the detection channel is VIC, the melting curve is a single peak, and when the Tm value of the single peak is 72.34±0.5, it indicates that the genotype of the detection site is type I. If the value of the single peak is 58.59±0.5, it indicates that the genotype of the site is type D. If the melting curve is a double peak, and the Tm values of the double peaks are 58.59±0.5 and 72.34±0.5 respectively, it indicates that the genotype of the site is type I / D.
[0103] The above specific corresponding relationships are shown in Table 4 below.
[0104] Table 4 Analysis results of the effectiveness of each gene locus detection
[0105]
[0106]
[0107] Example 2 Verification of the detection accuracy of each gene locus of the kit
[0108] 1. Test method:
[0109] 20 throat swab samples were collected, and each sample was tested by qPCR platform according to the method of Example 1. At the same time, each sample was sequenced for the 1165G>C site of the ADRB1 gene, the 100C>T site of the CYP2D6*10 gene, the 1075A>C site of the CYP2C9*3 gene, the 6986A>G site of the CYP3A5*3 gene, the 1166A>C site of the AGTR1 gene, the 2238T>C site of the NPPA gene, and the ACE (I / D) gene.
[0110] 2. Test results and analysis
[0111] The results show that the results obtained by the detection method of the kit of the present invention are completely consistent with the first-generation sequencing results, indicating that the kit of the present invention and its detection method can accurately detect the ADRB1 gene 1165G>C site, CYP2D6*10 gene 100C>T site, CYP2C9*3 gene 1075A>C site, CYP3A5*3 gene 6986A>G site, AGTR1 gene 1166A>C site, NPPA gene 2238T>C site, and ACE (I / D) gene genotype in the sample, which not only greatly improves the detection efficiency, but also has high detection accuracy.
[0112] Table 5 Sample test results
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119] Example 3 Sensitivity test of the kit
[0120] 1. Experimental methods
[0121] The positive standards (heterozygous mutant genotypes) of the seven homemade targets were 10 6 Serial dilutions to 10 copies / mL 3 copies / mL, 10 2 The template was 10 copies / mL and 10 copies / mL. The negative sample was TE Buffer. The diluted template and negative sample were amplified using the kit described in Example 1, respectively, and the amplification conditions were the same as those in Example 1.
[0122] 2. Experimental results and analysis
[0123] According to the result judgment standard in Example 1, the results of the sensitivity of 7 target detection are shown in Table 6. As can be seen from Table 6, when the target template is 10 copies / mL, the kit described in Example 1 can still use it as a template for amplification. It can be seen that in the case of low-concentration templates, the kit of the present invention can still perform effective detection, so the kit has a high sensitivity.
[0124] Table 6 Sensitivity results
[0125]
[0126]
[0127] Example 4 Specificity test of the kit
[0128] 1. Experimental methods
[0129] Relevant pathogens in human throat swabs, saliva and blood, influenza A virus, influenza B virus, parainfluenza virus, adenovirus, Mycoplasma pneumoniae, Chlamydia pneumoniae, respiratory syncytial virus, human rhinovirus, Staphylococcus aureus, Candida albicans, Streptococcus pneumoniae, hepatitis B virus, dengue virus, human immunodeficiency virus, Treponema pallidum, Ebola virus, Zika virus, yellow fever virus, Aspergillus, Cryptococcus were selected as simulated interference samples, and the concentration of homemade 10 6 The specificity detection of the plasmid was performed by the method of Example 1.
[0130] 2. Experimental results and analysis
[0131] The experimental results showed that except for the positive control, the results of other samples were negative, which proved that the kit of the present invention has high specificity and has no cross reaction with other pathogen nucleic acids in this example.
[0132] Example 5 Performance comparison of the kits of different comparative examples
[0133] 1. Experimental methods
[0134] This experiment provides kits of Comparative Example 1 and Comparative Example 2. The difference between these two kits and the kit of Example 1 is that different primer-probe compositions are used, as shown in Table 7. The fluorescent probes on each primer probe of each control group refer to Example 1 for comparative analysis, and the preparation method of the kit is the same as that of the aforementioned example.
[0135] Table 7 Primer probes for the control group
[0136]
[0137]
[0138] The test kit prepared in Example 1 of the present application, and the test kits prepared in control group 1 and control group 2 were respectively used to experiment on sample No. 15 of Example 2, and the experimental effects of each test kit were compared.
[0139] 2. Experimental results and analysis
[0140] The experimental results of the test kits prepared by control group 1 and control group 2 on the 15 samples of Example 2 are shown in Table 8.
[0141] Compared with Example 1, the problems existing in Comparative Example 1 and Comparative Example 2 are as follows: no melting peak appears at the 100C>T site of the CYP2D6*10 gene of Comparative Example 1 and Comparative Example 2, no melting peak appears at the 1075A>C site of the CYP2C9*3 gene of Comparative Example 1 and Comparative Example 2, the 6986A>G site of the CYP3A5*3 gene of Comparative Example 1 and Comparative Example 2 is a single peak, the 1165G>C site of the ADRB1 gene of Comparative Example 1 and Comparative Example 2 is a single peak, no melting peak appears at the 1166A>C site of the AGTR1 gene of Comparative Example 1 and Comparative Example 2, the 2238T>C site of the NPPA gene of Comparative Example 1 and Comparative Example 2 is a single peak, and the ACE(I / D) gene of Comparative Example 1 and Comparative Example 2 is a single peak.
[0142] The above results show that the kit prepared by the present invention has accurate results, high sensitivity, high specificity of primer design, and can be used for the detection of polymorphisms of seven hypertension-related gene loci at the same time. The results also show that the primer probe sequence in the primer-probe combination in the kit of the present invention cannot be replaced at will, otherwise it is impossible to achieve the simultaneous detection of polymorphisms of seven hypertension-related gene loci.
[0143] Table 8 Experimental results of the control group
[0144]
[0145] It is understandable that those skilled in the art can make equivalent substitutions or changes based on the technical solution and concept of the present invention, and all these changes or substitutions should fall within the protection scope of the claims attached to the present invention.
Claims
1. A primer-probe combination for detecting gene polymorphism of hypertension medication, It is characterized in that The invention includes the following pairs of primers and probes for detecting the 1165G>C site of ADRB1 gene, the 100C>T site of CYP2D6*10 gene, the 1075A>C site of CYP2C9*3 gene, the 6986A>G site of CYP3A5*3 gene, the 1166A>C site of AGTR1 gene, the 2238T>C site of NPPA gene, and the ACE(I / D) gene: The primer probes used to detect the 100C>T site of the CYP2D6*10 gene are: a forward primer F1 whose sequence is shown in SEQ ID NO.1, a reverse primer R1 whose sequence is shown in SEQ ID NO.2, and a fluorescent probe T1 whose sequence is shown in SEQ ID NO.3; The primer probes used to detect the 1075A>C site of the CYP2C9*3 gene are: a forward primer F2 whose sequence is shown in SEQ ID NO.4, a reverse primer R2 whose sequence is shown in SEQ ID NO.5, and a fluorescent probe T2 whose sequence is shown in SEQ ID NO.6; The primer probes used to detect the 6986A>G site of the CYP3A5*3 gene are: a forward primer F3 whose sequence is shown in SEQ ID NO.7, a reverse primer R3 whose sequence is shown in SEQ ID NO.8, and a fluorescent probe T3 whose sequence is shown in SEQ ID NO.9; The primer probes used to detect the 1165G>C site of the ADRB1 gene are: a forward primer F4 whose sequence is shown in SEQ ID NO.10, a reverse primer R4 whose sequence is shown in SEQ ID NO.11, and a fluorescent probe T4 whose sequence is shown in SEQ ID NO.12; The primers and probes used to detect the 1166A>C site of the AGTR1 gene are: a forward primer F5 having a sequence as shown in SEQ ID NO.13, a reverse primer R5 having a sequence as shown in SEQ ID NO.14, and a fluorescent probe T5 having a sequence as shown in SEQ ID NO.15; The primers and probes used to detect the 2238T>C site of the NPPA gene are: a forward primer F6 having a sequence as shown in SEQ ID NO.16, a reverse primer R6 having a sequence as shown in SEQ ID NO.17, and a fluorescent probe T6 having a sequence as shown in SEQ ID NO.18; The primer probes used to detect the ACE (I / D) gene are: a forward primer F7 whose sequence is shown in SEQ ID NO.19, a reverse primer R7 whose sequence is shown in SEQ ID NO.20, and a fluorescent probe T7 whose sequence is shown in SEQ ID NO.
21.
2. The primer-probe combination for detecting gene polymorphism of hypertension medication according to claim 1, It is characterized in that It also includes primer probes for detecting internal reference genes: an upstream primer RP-F with a sequence as shown in SEQ ID NO.22, a downstream primer RP-R with a sequence as shown in SEQ ID NO.23, and a fluorescent probe RP-P with a sequence as shown in SEQ ID NO.
24.
3. The primer-probe combination for detecting gene polymorphism of hypertension medication according to claim 1, It is characterized in that The 5' end of the fluorescent probe is labeled with a fluorescent reporter group, and the 3' end of the fluorescent probe is labeled with a fluorescent quencher group. The fluorescent reporter group is selected from any one of FAM, ROX, CY5 and VIC; and the quencher group is BHQ1, BHQ2 or BHQ3.
4. The primer-probe combination for detecting gene polymorphism of hypertension medication according to claim 1, It is characterized in that The fluorescent probes for the 1075A>C site of the CYP2C9*3 gene and the 100C>T site of the CYP2D6*10 gene were labeled with the FAM fluorescent group at the 5' end and the quencher group BHQ1 at the 3' end; the fluorescent probes for the 6986A>G site of the CYP3A5*3 gene and the 1165G>C site of the ADRB1 gene were labeled with the CY5 fluorescent group at the 5' end and the quencher group BHQ3 at the 3' end; the fluorescent probes for the 1166A>C site of the AGTR1 gene and the 2238T>C site of the NPPA gene were labeled with the ROX fluorescent group at the 5' end and the quencher group BHQ2 at the 3' end; the fluorescent probes for the ACE(I / D) gene and RP were labeled with the VIC fluorescent group at the 5' end and the quencher group BHQ1 at the 3' end.
5. A kit for detecting gene polymorphism of hypertension medication, It is characterized in that The invention comprises the primer-probe combination according to any one of claims 1 to 4.
6. The kit according to claim 5, It is characterized in that include: A reaction premix and an enzyme mixture, wherein the reaction premix comprises the primer-probe combination according to any one of claims 1 to 4 and a reaction buffer.
7. The kit according to claim 6, It is characterized in that Also includes: Positive control and negative control; the positive control comprises 7 kinds of gene heterozygous mutation genotype sequences and RP gene sequence, and the negative control is TE Buffer.
8. Use of the kit for detecting gene polymorphism of hypertension medication as claimed in claim 5 in detecting gene polymorphism of hypertension medication.
9. The use according to claim 8, It is characterized in that The samples to be tested include but are not limited to at least one of throat swabs, saliva and blood.
10. A method for detecting gene polymorphisms in hypertension medication, It is characterized in that The following steps are involved: S1, adding the sample to be tested into a PCR reaction tube containing the primer-probe combination as claimed in claim 1 and a PCR reaction solution, mixing and then amplifying; S2. Detect the genotype of the target detection site according to the difference in Tm values of the melting curves of each channel in the PCR reaction system. Optionally, the amplification conditions of step S1 are: (1) Pre-denaturation at 95°C for 30 seconds; (2) 95°C for 5 seconds, 60°C for 10 seconds, for 40 cycles; (3) 95°C for 3 minutes; 40°C for 3 minutes; (4) Melting program: 45°C-80°C, heating rate 0.05°C / s. In the above step (4), fluorescence is detected at 45°C-80°C, and the detection channels are: FAM, ROX, CY5, and VIC; Optionally, in step S2, the specific analysis and judgment method is: The site to be detected is the 100C>T site of the CYP2D6*10 gene, the detection channel is FAM, the melting curve is a single peak, and when the Tm value of the peak is 73, it indicates that the genotype of the detection site is TT. If the value of the single peak is 70, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 70 and 73 respectively, it indicates that the genotype of the site is TC. The site to be detected is the 1075A>C site of the CYP2C9*3 gene, the detection channel is FAM, the melting curve is a single peak, and when the Tm value of the single peak is 54, it indicates that the genotype of the detection site is AA. If the value of the single peak is 63, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 54 and 63 respectively, it indicates that the genotype of the site is AC. The site to be detected is the 6986A>G site of the CYP3A5*3 gene, the detection channel is Cy5, the melting curve is a single peak, and when the Tm value of the single peak is 68, it indicates that the genotype of the detection site is AA. If the value of the single peak is 63, it indicates that the genotype of the site is GG. If the melting curve is a double peak, and the Tm values of the double peaks are 68 and 63 respectively, it indicates that the genotype of the site is AG. The site to be detected is the 1165G>C site of the ADRB1 gene, the detection channel is Cy5, the melting curve is a single peak, and when the Tm value of the single peak is 60, it indicates that the genotype of the detection site is GG. If the value of the single peak is 65, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 60 and 65 respectively, it indicates that the genotype of the site is GC. The site to be detected is the AGTR1 gene 1166A>C site, the detection channel is ROX, the melting curve is a single peak, and when the Tm value of the single peak is 58, it indicates that the genotype of the detection site is AA. If the value of the single peak is 65, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 58 and 65 respectively, it indicates that the genotype of the site is AC. The site to be detected is the NPPA gene 2238T>C site, the detection channel is ROX, the melting curve is a single peak, and when the Tm value of the single peak is 53, it indicates that the genotype of the detection site is TT. If the value of the single peak is 60, it indicates that the genotype of the site is CC. If the melting curve is a double peak, and the Tm values of the double peaks are 53 and 60 respectively, it indicates that the genotype of the site is TC. The site to be detected is the ACE (I / D) gene, the detection channel is VIC, the melting curve is a single peak, and when the Tm value of the single peak is 72, it indicates that the genotype of the detection site is type I. If the value of the single peak is 58, it indicates that the genotype of the site is type D. If the melting curve is a double peak, and the Tm values of the double peaks are 58 and 72 respectively, it indicates that the genotype of the site is type I / D.
